Search Result

Results for "

IAPs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (6) AMPK (1) Androgen Receptor (3) Apoptosis (23) Autophagy (3) Bcl-2 Family (1) Bcr-Abl (13) Caspase (9) CD47 (2) Drug Derivative (2) Drug Intermediate (1) E1/E2/E3 Enzyme (1) E3 Ligase Ligand-Linker Conjugates (27) EGFR (1) Estrogen Receptor/ERR (4) FABP (1) FAK (1) FLT3 (1) FXR (2) GLUT (1) HSP (1) IAP (42) Isotope-Labeled Compounds (2) JNK (3) Ligands for E3 Ligase (11) Ligands for Target Protein for PROTAC (12) MDM-2/p53 (1) MHC (3) mTOR (1) NF-κB (3) P-glycoprotein (3) PANoptosis (1) PARP (2) PERK (1) PI3K (4) PROTAC Linkers (2) PROTACs (17) Proteasome (1) RAR/RXR (1) Ras (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) RIP kinase (1) SNIPERs (30) SOD (1) Survivin (2) Target Protein Ligand-Linker Conjugates (10) TNF Receptor (1) VEGFR (1) YAP (10)
By Research Areas:	Cancer (130) Infection (2) Inflammation/Immunology (7) Metabolic Disease (1) Neurological Disease (1)
Click Chemistry:	PROTAC Synthesis (3)

141

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15454

Xevinapant 10+ Cited Publications AT-406; Debio 1143; SM-406	IAP Apoptosis	Cancer
Xevinapant (AT-406) is a potent and orally bioavailable Smac mimetic and an antagonist of *IAPs, and it binds to XIAP, cIAP1, and cIAP2 proteins with K_i* of 66.4, 1.9, and 5.1 nM, respectively.

HY-15518

LCL161 Maximum Cited Publications 41 Publications Verification	IAP	Cancer
LCL161 is a *IAP* inhibitor which inhibits XIAP in HEK293 cell and cIAP1 in MDA-MB-231 cell with IC₅₀s of 35 and 0.4 nM, respectively.

HY-12600

AZD5582 15+ Cited Publications	IAP Apoptosis	Cancer
AZD5582 is an antagonist of the inhibitor of apoptosis proteins (IAPs), which binds to the BIR3 domains cIAP1, cIAP2, and XIAP with IC₅₀s of 15, 21, and 15 nM, respectively. AZD5582 induces apoptosis .

HY-125593

Dasminapant APG-1387	IAP Apoptosis	Cancer
Dasminapant (APG-1387), a bivalent SMAC mimetic and an *IAP* antagonist, blocks the activity of IAPs family proteins (XIAP, cIAP-1, cIAP-2, and ML-IAP). Dasminapant induces degradation of cIAP-1 and XIAP proteins, as well as caspase-3 activation and PARP cleavage, which leads to apoptosis. Dasminapant can be used for the research of hepatocellular carcinoma, ovarian cancer, and nasopharyngeal carcinoma .

HY-15835

CUDC-427 5 Publications Verification GDC-0917	IAP	Cancer
CUDC-427 is a potent second-generation pan-selective *IAP* antagonist, used for treatment of various cancers.

HY-13638

GDC-0152 10+ Cited Publications	IAP	Cancer
GDC-0152 is a potent *IAPs* inhibitor, and binds to the BIR3 domains of XIAP, cIAP1, cIAP2 and the BIR domain of *ML-IAP* with K_i values of 28 nM, 17 nM, 43 nM and 14 nM, respectively.

HY-124181

SM-1295	IAP Apoptosis	Cancer
SM-1295 is an inhibitor of apoptosis protein (IAP) antagonist, with K_d values of 3077 nM, 3.2 nM and 9.5 nM for XIAP-BIR3, c-IAP1-BIR3 and c-IAP2-BIR3, respectively .

HY-P990131

*Anti-Mouse CD47/IAP* Antibody (MIAP301)** 1 Publications Verification	CD47	Infection Inflammation/Immunology Cancer
Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse *CD47/IAP* IgG2a monoclonal antibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for researches on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis .

HY-113534

MV1	IAP Apoptosis	Cancer
MV1 is an antagonist of *IAP* (inhibitor of apoptosis protein), leads to protein knockdown of HaloTag-fused proteins when combined with HaloTag ligand .

HY-136269

A 410099.1, amine-Boc hydrochloride	E3 Ligase Ligand-Linker Conjugates	Cancer
A 410099.1, amine-Boc hydrochloride is a functionalized IAP ligand and can be used for the synthesis of PROTACs, such as PROTACs targeting BTK (PROTACs 4 and 5) .

HY-133558

VII-31 2 Publications Verification	E1/E2/E3 Enzyme Apoptosis	Cancer
VII-31 is a potent NEDDylation pathway activator to inhibit the tumor progression in vitro and in vivo. VII-31 induces apoptosis via intrinsic and extrinsic pathways .

HY-125378

SBP-0636457 SBI-0636457; SB1-0636457	IAP	Cancer
SBP-0636457 (SB1-0636457) is a SMAC mimetic, and as an *IAP* antagonist. SBP-0636457 binds to the BIR-domains of the IAP proteins, with a K_i of 0.27 μM. SBP-0636457 can be used for the research of solid tumors and hematologic cancers .

HY-P990132

*Anti-Mouse/Rat/Human CD47/IAP* Antibody (MIAP410)**	CD47	Inflammation/Immunology Cancer
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an anti-mouse/rat/human *CD47/IAP* IgG1 monoclonal antibody. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can increase the infiltration of immune cells. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) may interfere with wound healing. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can be used for researches on cancer and inflammation conditions such as breast cancer and intestinal mucosal repair .

HY-111844

PROTAC RAR Degrader-1	PROTACs SNIPERs RAR/RXR	Neurological Disease Metabolic Disease Cancer
PROTAC RAR degrader-1 (Compound 9) is a potent and selective RAR PROTAC Degrader consisting of apoptotic protein inhibitors (IAPs) ligands. IAPs-based degraders are also known as SNIPERs. PROTAC RAR Degrader-1 reduces RARα levels in HT1080 cells in a concentration-dependent manner but is blocked by the proteasome inhibitor MG132 (HY-13259). PROTAC RAR Degrader-1 can be used in the study of nuclear receptor-related diseases. (Pink: RAR ligand 1 (HY-111843); Black: Linker (HY-140189); Blue: IAPs Ligand (HY-B0134)) .

HY-43962

Androgen receptor ligand 3	Ligands for Target Protein for PROTAC Androgen Receptor	Cancer
Androgen receptor ligand 3 is an androgen receptor (AR) ligand. Androgen receptor ligand 3 is linked to an IAP ligand via a linker to form an ERα PROTAC degrader.

HY-111876

SNIPER(TACC3)-1	SNIPERs	Cancer
SNIPER(TACC3)-1 targets the TACC3 protein for degradation via the ubiquitin-proteasome pathway based on *IAP* ligand. SNIPER(TACC3)-1 induces cancer cell death .

HY-110346

AZD5582 dihydrochloride 15+ Cited Publications	IAP Apoptosis	Cancer
AZD5582 dihydrochloride is an antagonist of the inhibitor of apoptosis proteins (IAPs), which binds to the BIR3 domains cIAP1, cIAP2, and XIAP with IC₅₀s of 15, 21, and 15 nM, respectively. AZD5582 induces apoptosis .

HY-78144

4-Methylsalicylic acid	Drug Derivative Drug Intermediate	Inflammation/Immunology
4-Methylsalicylic acid is a methyl derivative of Salicylic acid (HY-B0167). 4-Methylsalicylic acid derivatives inhibit the activity of alkaline phosphatases such as TNAP and IAP. 4-Methylsalicylic acid derivatives exhibit immunosuppressive activity .

HY-130991

K-Ras ligand-Linker Conjugate 6	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 6 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 6 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .

HY-151966

TD1092	PROTACs IAP Caspase PANoptosis	Cancer
TD1092 is a pan-IAP degrader, degrades cIAP1, cIAP2, and XIAP. TD1092 activates Caspase 3/7, and promotes cancer cells apoptosis via *IAP* degradation. TD1092 inhibits TNFα mediated NF-κB pathway and reduces the phosphorylation of IKK, IkBα, p65, and p38. TD1092 can act as PROTAC, and is used for cancer research .

HY-111857

Dasatinib carbaldehyde BMS-354825 carbaldehyde; PROTAC ABL binding moiety 4	Ligands for Target Protein for PROTAC	Cancer
Dasatinib carbaldehyde (BMS-354825 carbaldehyde), the Dasatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .

HY-111877

SNIPER(TACC3)-2	SNIPERs	Cancer
SNIPER(TACC3)-2 targets the TACC3 protein for degradation via the ubiquitin-proteasome pathway based on *IAP* ligand. SNIPER(TACC3)-2 induces cancer cell death .

HY-128809

cIAP1 ligand 2 E3 ligase Ligand 11	Ligands for E3 Ligase	Cancer
cIAP1 ligand 2 is the LCL161 derivative based IAP ligand. cIAP1 ligand 2 can be connected to the ABL ligand for protein by a linker to form SNIPER.

HY-150825

CST530	IAP Ligands for E3 Ligase	Cancer
CST530 is an inhibitor of apoptosis protein (IAP) antagonist. CST530 is an IAP-type Ligands for E3 Ligase. CST530 binds to the BIR3 domain of IAP and interferes with its function, thereby promoting the ubiquitination and degradation of cIAP1. CST530 can be used to prepare PROTACs .

HY-125378A

(7R)-SBP-0636457 (7R)-SBI-0636457; (7R)-SB1-0636457	IAP	Cancer
(7R)-SBP-0636457 is the isomer of SBP-0636457 (HY-125378), and can be used as an experimental control. SBP-0636457 (SB1-0636457) is a SMAC mimetic, and as an *IAP* antagonist. SBP-0636457 binds to the BIR-domains of the IAP proteins, with a K_i of 0.27 μM. SBP-0636457 can be used for the research of solid tumors and hematologic cancers .

HY-120434

AEG40826 HGS1029	IAP	Cancer
AEG40826 (HGS1029), a second mitochondria-derived activator of caspases (SMAC) mimetic, is an inhibitor of apoptosis (IAP) inhibitor. AEG40826 degrades cellular IAP1 (cIAP1) and blocks TNF-α pro-survival signaling. AEG40826 can be used for cancer research .

HY-131188

PROTAC Bcl-xL degrader-1	PROTACs Bcl-2 Family	Cancer
PROTAC Bcl-xL degrader-1 is a PROTAC that comprises a Bcl-xL (Bcl-2 family member) ligand binding group, a linker and an *IAP* E3 ligases binding group. PROTAC Bcl-xL degrader-1 is a potent Bcl-xL degrader, and shows toxicity for human platelets and MyLa 1929 cells with IC₅₀ values of 62 nM and 8.5 μM, respectively .

HY-111848A

PROTAC AR Degrader-4 TFA	SNIPERs PROTACs Androgen Receptor	Cancer
PROTAC AR Degrader-4 comprises a *IAP* ligand binding group, a linker and an Androgen Receptor (AR) binding group. PROTAC AR Degrader-4 is an AR degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs) .

HY-111848

PROTAC AR Degrader-4	SNIPERs PROTACs Androgen Receptor	Cancer
PROTAC AR Degrader-4 comprises a *IAP* ligand binding group, a linker and an Androgen Receptor (AR) binding group. PROTAC AR Degrader-4 is an AR degrader. Degradation inducers based on cIAP1 are called specific and non-genetic IAP-dependent protein erasers (SNIPERs) .

HY-139865

142I5	Apoptosis	Cancer
142I5 is a potent *ML-IAP* Lys-covalent inhibitor with an IC₅₀ value of 11 nM.

HY-111872

SNIPER(ABL)-020	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-020, conjugating Dasatinib (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein .

HY-111840

PROTAC CRABP-II Degrader-1	SNIPERs PROTACs	Cancer
PROTAC CRABP-II Degrader-1 is a potent cellular retinoic acid binding protein (CRABP-II) degrader based on *IAP* ligand .

HY-136010

RIP2 Kinase Inhibitor 4	RIP kinase PROTACs	Inflammation/Immunology
RIP2 Kinase Inhibitor 4 is a potent and selective RIPK2 PROTAC. RIP2 Kinase Inhibitor 4 effectively degrades RIPK2 (pIC₅₀ of 8) and inhibits the release of related TNF-α .

HY-111860

SNIPER(ABL)-013	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-013, conjugating GNF5 (ABL inhibitor) to Bestatin (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 20 μM .

HY-111861

SNIPER(ABL)-024	SNIPERs Bcr-Abl	Cancer
SNIPER(ABL)-024, conjugating GNF5 (ABL inhibitor) to LCL161 derivative (IAP ligand) with a linker, induces the reduction of BCR-ABL protein with a DC₅₀ of 5μM .

HY-175446

GDC-0152-acetamide	IAP Apoptosis	Cancer
GDC-0152-acetamide is a pan-inhibitor of apoptosis protein (IAP) antagonist. GDC-0152-acetamide induces cIAP1/2 autoubiquitination and degradation, activating the non-canonical NF-κB pathway to promote TNF-α secretion and tumor cell apoptosis. GDC-0152-acetamide is promising for research of ERα-positive breast cancer .

HY-111850

Bestatin-amido-Me PROTAC IAP binding moiety 1	Ligands for E3 Ligase	Cancer
Bestatin-amido-Me, the Bestatin-based IAP ligand, binds to ABL inhibitor via a linker to form SNIPER .

HY-111842

PROTAC CRABP-II Degrader-3	SNIPERs PROTACs	Cancer
PROTAC CRABP-II Degrader-3 is a potent cellular retinoic acid binding protein (CRABP-II) degrader based on *IAP* ligand .

HY-111849

Imatinib carbaldehyde CGP-57148B carbaldehyde; STI571 carbaldehyde; PROTAC ABL binding moiety 1	Ligands for Target Protein for PROTAC	Cancer
Imatinib carbaldehyde (CGP-57148B carbaldehyde), the Imatinib (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .

HY-118522

TP-110	Proteasome NF-κB Caspase PARP IAP Apoptosis	Cancer
TP-110 is a proteasome inhibitor. TP-110 specifically inhibits the protease-like activity of the 20S proteasome, but does not affect the trypsin-like or peptidyl-glutamyl peptide hydrolysis activity. TP-110 inhibits the NF-κB pathway, activates caspase-8, -9, and -3, and causes PARP cleavage, significantly reducing the levels of cIAP-1 and XIAP. TP-110 causes cell cycle arrest at the G2/M phase and promotes apoptosis of cancer cells. TP-110 can be used in cancer research of prostate cancer and multiple myeloma, etc .

HY-131178

HG-7-85-01-NH2	SNIPERs Ligands for Target Protein for PROTAC Bcr-Abl	Cancer
HG-7-85-01-NH2 is the HG-7-85-01 (ABL inhibitor) based moiety, binds to IAP ligand via a linker to form SNIPER .

HY-128818

cIAP1 Ligand-Linker Conjugates 5 E3 ligase Ligand-Linker Conjugates 39	E3 Ligase Ligand-Linker Conjugates	Cancer
cIAP1 Ligand-Linker Conjugates 5 incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 5 can be used to design SNIPERs .

HY-176441

E3 ligase Ligand 66	Ligands for E3 Ligase	Infection
E3 ligase Ligand 66 is an E3 ligase ligand that can be used to recruit IAP proteins. E3 ligase Ligand 66 can be linked to SARS-CoV-2 Mpro ligand 1 (HY-176442) through a linker to form PROTAC BP-198 (HY-176440) .

HY-123870

MX107	Survivin IAP NF-κB	Inflammation/Immunology Cancer
MX107 is a selective and potent survivin inhibitor that suppresses triple-negative breast cancer (TNBC) cell proliferation. MX107 induces degradation of survivin and inhibitor-of-apoptosis proteins (IAPs), which inhibits nuclear factor κB (NF-κB) activation induced by DNA damage. MX107 enhances tumoricidal efficacy of genotoxic treatments synergized with chemotherapeutic drugs .

HY-129776

K-Ras ligand-Linker Conjugate 2	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 2 incorporates a ligand for K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 2 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .

HY-129775

K-Ras ligand-Linker Conjugate 1	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 1 incorporates a ligand for K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 1 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells .

HY-177389

IAP ligand 5	Ligands for Target Protein for PROTAC	Cancer
IAP ligand 5 is a *IAP* ligand. IAP ligand 5 can be used to synthesize PROTAC ERα Degrader-2 (HY-111846).

HY-136272

A 410099.1 amide-PEG3-amine-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
A 410099.1 amide-PEG3-amine-Boc is a functionalized IAP ligand for PROTACs that incorporates an IAP ligand and an amide-PEG3 linker with terminal amine. A 410099.1 amide-PEG3-amine-Boc can conjugates with target protein ligands.

HY-136273

A 410099.1 amide-PEG2-amine-Boc	E3 Ligase Ligand-Linker Conjugates	Cancer
A 410099.1 amide-PEG2-amine-Boc is a functionalized IAP ligand for PROTACs that incorporates an IAP ligand and an amide-PEG3 linker with terminal amine. A 410099.1 amide-PEG2-amine-Boc can conjugates with target protein ligands.

HY-136274

Boc-A 410099.1 amide-alkylC4-amine	E3 Ligase Ligand-Linker Conjugates	Cancer
Boc-A 410099.1 amide-alkylC4-amine is a functionalized IAP ligand for PROTACs that incorporates an IAP ligand and an amide-alkylC4 linker with terminal amine. Boc-A 410099.1 amide-alkylC4-amine can conjugates with target protein ligands.

Cat. No.	Product Name

HY-L128

E3 Ligase Ligand Library

174 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation.

Although there are more than 600 E3 ubiquitin ligases, only several with small molecule ligands have been used for designing PROTACs, including Skp1-Cullin-F box complex containing Hrt1 (SCF), Von Hippel-Lindau tumor suppressor (VHL), Cereblon (CRBN), inhibitor of apoptosis proteins (IAPs), and mouse double minute 2 homolog (MDM2).

MCE carefully prepared a unique collection of 174 ligands for E3 ligase, which have been reported to be used in PROTAC design. MCE E3 ligase ligand library is a useful tool for PROTAC development.

HY-L003

Apoptosis Compound Library

3,407 compounds

Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease.

MCE designs a unique collection of 3,407 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

Cat. No.	Product Name	Target	Research Area

HY-P11828

Anticancer agent 324	Survivin Caspase Apoptosis	Cancer
Anticancer agent 324 is a Survivin inhibitor. Anticancer agent 324 competitively binds to Survivin’s linker region and triggers proteasomal IAP degradation. Anticancer agent 324 blocks Borealin binding and chromosomal passenger complex formation, and inhibits Survivin-CRM1 nuclear-cytoplasmic transport. Anticancer agent 324 activates extrinsic (caspase-8) and intrinsic (caspase-9) apoptotic pathways, activates executioner caspases-3 and caspases-7, and arrests cell cycle. Anticancer agent 324 can be used for the research of breast cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990131

*Anti-Mouse CD47/IAP* Antibody (MIAP301)** 1 Publications Verification	CD47	Infection Inflammation/Immunology Cancer
Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse *CD47/IAP* IgG2a monoclonal antibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for researches on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis .

HY-P990132

*Anti-Mouse/Rat/Human CD47/IAP* Antibody (MIAP410)**	CD47	Inflammation/Immunology Cancer
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an anti-mouse/rat/human *CD47/IAP* IgG1 monoclonal antibody. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can increase the infiltration of immune cells. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) may interfere with wound healing. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can be used for researches on cancer and inflammation conditions such as breast cancer and intestinal mucosal repair .

HY-P990188

Anti-Mouse MHC class II (I-A) Antibody (Y-3P)	MHC	Inflammation/Immunology
Anti-Mouse MHC class II (I-A) Antibody (Y-3P) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse MHC class II. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) reacts with mouse MHC Class II haplotypes I-Ab, I-Af, I-Ap, I-Aq, I-Ar, I-As, I-Au, I-Av, and weakly with I-Ak. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) blocks MHC class II and inhibits expansion of regulate T cells. Anti-Mouse MHC class II (I-A) Antibody (Y-3P) can be used for the immunology research .

HY-P990184

Anti-Mouse MHC Class II (βchain) Antibody (KL277)	MHC	Others
Anti-Mouse MHC Class II (βchain) Antibody (KL277) is a hamster/mouse-derived IgG type antibody inhibitor, targeting to mouse MHC Class II. Anti-Mouse MHC Class II (βchain) Antibody (KL277) reacts with mouse MHC Class II haplotypes I-Ab, I-Ad, I-Ap, I-Aq, I-Abu, and I-Abw. Anti-Mouse MHC Class II (βchain) Antibody (KL277) does not react with I-Aa, I-Ak, I-Af, I-Aj, I-As, or I-Atl haplotypes. Anti-Mouse MHC Class II (βchain) Antibody (KL277) can be used for western blot experiments .

HY-P990186

Anti-Mouse MHC Class II (I-Ak, I-Ar, I-Af, I-As,I-Ag7) Antibody (10-3.6.2)	MHC	Others
Anti-Mouse MHC Class II (I-Ak, I-Ar, I-Af, I-As,I-Ag7) Antibody (10-3.6.2) is a mouse-derived IgG2c κ type antibody inhibitor, targeting to mouse MHC Class II. Anti-Mouse MHC Class II (I-Ak, I-Ar, I-Af, I-As,I-Ag7) Antibody (10-3.6.2) reacts with mouse MHC Class II haplotypes I-Ak, I-Ar, I-Af, I-As, and I-Ag7. Anti-Mouse MHC Class II (I-Ak, I-Ar, I-Af, I-As,I-Ag7) Antibody (10-3.6.2) does not react with I-Ab, I-Ad, I-Ap, or I-Aq haplotypes. Anti-Mouse MHC Class II (I-Ak, I-Ar, I-Af, I-As,I-Ag7) Antibody (10-3.6.2) blocks MHC Class II and inhibits antigen proliferation responses. Anti-Mouse MHC Class II (I-Ak, I-Ar, I-Af, I-As,I-Ag7) Antibody (10-3.6.2) can be used for the research of immunology .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-107738

Guggulsterone Maximum Cited Publications 21 Publications Verification Z/E-Guggulsterone	Triterpenes Structural Classification Classification of Application Fields Terpenoids Plants Burseraceae Disease Research Fields Commiphora wightii Cancer	Apoptosis JNK Akt Caspase FXR Autophagy
Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt . Guggulsterone, a farnesoid X receptor (FXR) antagonist, with IC₅₀s of 24.06 μM and 39.05 μM for (-)-(E)-Guggulsterone (HY-N7781) and (Z)-Guggulsterone (HY-110066), respectively .

HY-W009141

1-Monopalmitin Glyceryl palmitate	Plants Source Classification	P-glycoprotein IAP PI3K Akt Caspase Apoptosis
1-Monopalmitin (Glyceryl palmitate) is an activator of the PI3K/Akt pathway and an inhibitor of P-glycoprotein (P-gp). 1-Monopalmitin can induce G2/M arrest and caspase-dependent apoptosis in cancer cells, while inhibiting *IAPs* protein expression. 1-Monopalmitin can increase drug accumulation by inhibiting P-gp activity in intestinal Caco-2 cells. 1-Monopalmitin has the ability to induce protective autophagy and apoptosis of lung cancer cells (IC₅₀=50-58 μg/mL), with low toxicity to normal cells .

HY-N2445

Flavokawain C 4 Publications Verification	Structural Classification Classification of Application Fields Piperaceae Plants Chalcones Flavonoids other families Phenols Polyphenols Piper methysticum G.Forst. Disease Research Fields Source Classification Cancer	Apoptosis Akt JNK PERK Caspase PARP MDM-2/p53 IAP Reactive Oxygen Species (ROS) SOD FABP Autophagy AMPK mTOR GLUT EGFR PI3K HSP VEGFR FAK
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic *IAP* proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of HSP90B1. Flavokawain C inhibits angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer .

HY-N6064

Polygalacin D 3 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Platycodon grandiflorus (Jacq.) A. DC. Campanulaceae Plants Disease Research Fields Cancer Source Classification	Apoptosis IAP
Polygalacin D (PGD) is a bioactive compound isolated from Platycodon grandiflorum with anticancer and anti-proliferative properties. PGD suppresses the expression of the *IAP* family of proteins including survivin, cIAP-1 and cIAP-2 and blocks the PI3K/Akt pathway by inhibiting the phosphorylation of GSK3β, Akt and the expression of PI3K. Polygalacin D induces apoptosis

HY-107738R

Guggulsterone (Standard) Z/E-Guggulsterone (Standard)	Triterpenes Structural Classification Terpenoids Plants Burseraceae Commiphora wightii	Apoptosis JNK Akt Caspase FXR Autophagy Reference Standards
Guggulsterone (Standard) is the analytical standard of Guggulsterone (HY-107738). This product is intended for research and analytical applications. Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt. Guggulsterone, a farnesoid X receptor (FXR) antagonist, with IC₅₀s of 24.06 μM and 39.05 μM for (-)-(E)-Guggulsterone (HY-N7781) and (Z)-Guggulsterone (HY-110066), respectively.

HY-W009141R

1-Monopalmitin (Standard) Glyceryl palmitate (Standard)	Plants Source Classification	Reference Standards Apoptosis P-glycoprotein PI3K IAP Caspase Akt
1-Monopalmitin (Glyceryl palmitate) (Standard) is the analytical standard of 1-Monopalmitin (HY-W009141). This product is intended for research and analytical applications. 1-Monopalmitin (Glyceryl palmitate) is an activator of the PI3K/Akt pathway and an inhibitor of P-glycoprotein (P-gp). 1-Monopalmitin can induce G2/M arrest and caspase-dependent apoptosis in cancer cells, while inhibiting *IAPs* protein expression. 1-Monopalmitin can increase drug accumulation by inhibiting P-gp activity in intestinal Caco-2 cells. 1-Monopalmitin has the ability to induce protective autophagy and apoptosis of lung cancer cells (IC₅₀=50-58 μg/mL), with low toxicity to normal cells .

Cat. No.	Product Name	Chemical Structure

HY-107447S

N-Deshydroxyethyl Dasatinib-d8
N-Deshydroxyethyl Dasatinib-d₈ is the deuterium labeled N-Deshydroxyethyl Dasatinib. N-Deshydroxyethyl Dasatinib (N-Deshydroxyethyl BMS-354825), the Dasatinib-based moiety, binds to IAP ligand via a linker to form SNIPER to degrade ABL .

HY-W009141S

1-Monopalmitin-d31

1-Monopalmitin-d₃₁ (Glyceryl palmitate-d₃₁) is the deuterium labeled 1-Monopalmitin (HY-W009141). 1-Monopalmitin (Glyceryl palmitate) is an activator of the PI3K/Akt pathway and an inhibitor of P-glycoprotein (P-gp). 1-Monopalmitin can induce G2/M arrest and caspase-dependent apoptosis in cancer cells, while inhibiting IAPs protein expression. 1-Monopalmitin can increase drug accumulation by inhibiting P-gp activity in intestinal Caco-2 cells. 1-Monopalmitin has the ability to induce protective autophagy and apoptosis of lung cancer cells (IC₅₀=50-58 μg/mL), with low toxicity to normal cells .

Cat. No.	Product Name		Classification

HY-181536

TEAD ligand 2		PROTAC Synthesis
TEAD ligand 2 is a target protein ligand that can be used for the synthesis of PROTACs, such as PROTAC TEAD1/IAP degrader-1 (HY-181534). PROTAC TEAD1/IAP degrader-1 is a potent TEAD1/IAP PROTAC degrader with anti-cancer activity .

HY-181534

*PROTAC TEAD1/IAP* degrader-1**		PROTAC Synthesis
PROTAC TEAD1/IAP degrader-1 (Compound A232) is a selective TEAD1 and cIAP1 PROTAC degrader, with DC₅₀ values of 14 nM and 270 nM, respectively. PROTAC TEAD1/IAP degrader-1 promotes the ubiquitination and degradation of TEAD1 and cIAP1. PROTAC TEAD1/IAP degrader-1 downregulates the expression of the TEAD-dependent gene CTGF. PROTAC TEAD1/IAP degrader-1 exhibits anticancer activity against mesothelioma .

HY-181530

IAP ligand 6		PROTAC Synthesis
IAP ligand 6 (A250) is an IAP ligand with a K_a value of 0.1 μM for the human XIAP BIR3 domain. IAP ligand 6 binds to the XIAP BIR3 domain and serves as an alkynylpyridine scaffold for the preparation of TEAD degraders that recruit IAP. IAP ligand 6 is applicable to research related to mesothelioma .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks